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Introduction
Anaplastic lymphoma kinase (ALK) targeting has been, 
undoubtedly, one of the most revolutionized fields among 
oncogene-addicted lung cancer patients. In the recent years 
we can number clinical trials, such as phase 3 randomized 
ALEX and ALTA-1L, which represent huge milestones 
in the therapeutic management of advanced ALK+ non-
small cell lung cancer (NSCLC) patients (1,2). Both these 
trials evaluated the activity of a second-generation tyrosine 
kinase inhibitor (TKI), respectively alectinib for ALEX 
and brigatinib for ALTA-1L, compared to first-generation 
TKI, crizotinib, the gold standard therapeutic choice for 
these patients (1-3). Indeed, more potent ALK inhibitors 
(ALKi) have been showing deeper and more durable 
disease control, leading to results hardly imaginable before 
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[i.e., median progression-free survival (PFS) of 34.8 months 
for patients receiving alectinib versus 10.9 crizotinib] (4). 
Based on these data, alectinib has been approved as first-line 
treatment option for ALK+ NSCLC patients and, likely, 
other actors will play major role in the upfront management 
of these patients. 
Despite these improvements in the advanced setting, 
a thick fog of uncertainty wraps around the role of 
ALK-targeting in early/locally advance stage of the disease 
and whether ALKi play any role in this scenario still remains 
vague. Therefore, ALK rearrangements are not routinely 
screened in patients’ specimens at these disease stages, unless 
required when enrolled within specific clinical trials (5). 
In early stages NSCLC, surgery still represents the 
potentially curative approach, aimed to eliminating all 
the radiological detectable tumor bulk. However, a large 
fraction of patients, roughly 50%, relapse with single or 
multiple metastases and die for lung cancer (5-year survival 
rate equal to 56%) (6). Having in mind these poor outcomes 
and lung cancer screening implementation in the very next-
future, which will increase fraction of surgical patients, is 
easy to gauge the urgent need of peri-operative (adjuvant 
and neo-adjuvant) treatment strategies capable to really 
impact on long-term patients’ survival benefit (7-9). That 
said, current standard approach in the adjuvant setting is 
still represented by cisplatin-doublet chemotherapy, based 
on a survival benefit of 5.4% at 5 years follow up (10).
Genomic complexity of lung adenocarcinoma is well 
characterized, supporting the evidence of different tumor 
entities with different biology, natural history and clinical 
behavior (11). Within oncogene-addicted tumors itself, 
fusions-positive lung cancers retain peculiar aspects, 
compared to mutation-driven cancers (e.g., EGFR+) 
(12,13). Thus, a deep understating of ALK fusions-
related clinical implications in early stage of the disease 
is mandatory, to precisely determine their prognostic 
relevance and, consequently, promote therapeutic strategies’ 
implementation that could impact on PFS and, more 
relevant, on overall survival (OS).
ALK rearrangement frequency (early and late 
stage)
Since the discovery of ALK translocations (mainly involving 
EML4 as partner gene) in NSCLC, this molecular 
event appeared to be a relative infrequent phenomenon, 
detectable in 2–7% of patients (14). Notably, almost all 
the dataset screened for ALK gene fusions were composed 
of surgically treated patients, having enough tumor tissue 
for comprehensive molecular analyses (15-17). In these 
and other surgical series ALK rearrangements are seldom 
identified, reporting a low frequency (<5% in more than 
300 samples), whilst percentage of positivity impressively 
increases looking at the advanced (stage IV) population, 
rising at 18% (18,19). Conversely, EGFR mutations 
detection remains around 15% across different disease 
stages (20,21). Multiple factors may justify this different 
behavior. A possible explanation is that ALK translocations, 
once associated with other genetic disrupting events, drive 
an aggressive metastasizing tumor phenotype, leading to its 
identification only at late stages of the disease. Supporting 
this hypothesis, also early stages ALK+ lung cancers 
appeared to be more spread than what initially thought: a 
recent retrospective analysis, performed on resected lung 
adenocarcinoma with clinical N0 (absence of computed 
tomography or positron emission tomography detectable 
lymph node involvement), revealed an higher percentage of 
pathological N1 or N2 stage (37%) in ALK+ cases compared 
to other subgroups (EGFR+, KRAS+ or WT) (22). 
ALK+ lung cancer patients are younger, never or light 
smoker, diagnosed mainly on advanced stage of the 
disease, bearing adenocarcinoma histology with peculiar 
aspects: solid or sheet-like pattern, with “signet-ring” cells 
and invasive mucinous aspects, similar to other fusion-
positive subgroups (i.e., ROS+ or RET+) (13,17-19); thus, 
identifying a subgroup of tumors with morphological 
aspects denoting itself a more aggressive phenotype (23,24).
Different authors investigated the prognostic relevance 
of oncogene-addiction in early-stage lung cancers, but a 
general consensus has not been reached due to conflicting 
results. Identification of the right comparator group seems 
to be relevant: results of an European platform screening, 
conducted mainly in a smoker population, identifies ALK 
positivity (either by IHC or FISH) as predictor of better 
OS, whereas in other studies, evaluating never-smoker 
populations, the presence of ALK translocations resulted to 
be associated with poor disease free survival (DFS) (25-27). 
Similarly, other studies conducted on resected lung cancers 
highlight the association between ALK positivity and 
reduced recurrence free survival (RFS) or DFS compared 
to EGFR+ patients, although no differences in OS have 
been reported (13,28,29). Multiple factors can potentially 
jeopardize the prognostic interpretation of ALK fusions 
in surgical patients: retrospective nature of these studies, 
heterogeneity of comparator (smokers/never-smokers, 
oncogenic drivers, different stages) and limited number of 
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ALK+ patients. Extended follow-up, prospective and wider 
validation analyses, including different oncogene-addicted 
subgroups, could corroborate the evidence of a negative clinical 
impact of ALK gene translocations. Nevertheless, the undoubted 
higher number of disease recurrences in this patients’ subgroup 
spurs scientific community to implement peri-operative 
strategies aiming to a better disease control (9,30). 
Data on ALK inhibitors in the metastatic setting
Multiple ALK inhibitors are nowadays available in the 
clinical arena for advanced ALK+ lung cancer patients. Even 
though large clinical data are available for each compound 
and molecular mechanisms of resistance have been depicted, 
nevertheless a clear sequential strategy of administration is 
still missing.
Initially, crizotinib (Xalkori®), a first generation ALK/
ROS1 inhibitor active also against c-MET, was approved 
by FDA in 2011 and EMA in 2012 as standard treatment 
for lung cancers harboring ALK fusions, identified through 
a companion diagnostic assay. Standard drug dosage is 
250 mg bid, based on results of randomized phase III trial 
Profile 1014, for both patients progressing to chemotherapy 
or treatment-naïve (3,31).
Ceritinib (Zykadia®) was approved by FDA in 2014, and 
EMA in 2015, for ALK+ patients progressing or intolerant 
to crizotinib due to an improved PFS compared to 
chemotherapy (5.4 vs. 1.6 months) (32); moreover, based on 
ASCEND-4 trial’s results, ceritinib got the reimbursement 
as first-line option (33). Initial indication was of 750 mg 
once daily in fasting patients, but recent ASCEND-8 results 
reported equal efficacy and an improved tolerability at 450 
or 600 mg once daily with a low-fat meal (34).
Alectinib (Alecensa®), a potent and selective ALK/
RET inhibitor, was initially approved in 2015 for patients 
progressing or intolerant to crizotinib therapy, based on 
early results of a Japanese phase I–II clinical study (35,36). 
In 2017, phase III ALEX trial results, as above reported, 
pushed the alectinib approval in first-line setting, at dosage 
of 600 mg bid, for ALK+ patients reporting a better toxicity 
profile compared to other TKI and an overwhelming PFS (1,4).
Brigatinib (Alunbrig®), an ALK and mutated EGFR 
inhibitor, received an accelerated approval by FDA in 
2017 and EMA in 2018 as second line treatment for ALK+ 
patients, at dosage of 90 mg daily in a run-in phase of 
7 days and after at 180 mg daily (37). Last year have been 
published results of phase III ALTA-1L trial confirming a 
superior activity of brigatinib versus crizotinib as upfront 
treatment in ALK+ patients (2).
Lastly, lorlatinib (Lorbrena®), a third generation ALKi 
with a high affinity for ALK and ROS-1, had recently got 
approval by FDA in 2018 and EMA in 2019 as third line 
treatment for patients who received crizotinib and at least 
one more compound or as second line option for patients 
progressing to second-generation ALKi administered 
upfront (38). However, in different European countries still 
remain available only under compassionate use. Ongoing 
phase III trial is evaluating the activity of this more potent 
compound as initial therapeutic strategy.
Efforts and challenges exploring adjuvant ALK 
inhibitors
If diverse efforts have been applied to understand EGFR 
inhibitors’ role in the adjuvant setting, clinical trials in the 
ALK+ disease scenario are much more limited (39-41). 
Currently recruiting studies in adjuvant setting for 
ALK-rearranged patients are two phase III clinical 
trials: ALCHEMIST (NCT02194738) and ALINA 
(NCT03456076). The first one, taking advantage of 
wide genetic screening, enrolls stage IB (T ≥4 cm)-IIIA 
surgical treated patients after completion of standard of 
care treatments (chemotherapy and/or radiotherapy). 
ALK+ patients are randomized to receive crizotinib (at 
classical schedule of 250 mg bid) versus observation, up to 
24 months of treatment, in absence of disease progression 
or unacceptable toxicities. Other two experimental arms 
contemplate erlotinib for EGFR mutated patients and 
nivolumab for double negative subgroup. OS is the first 
endpoint and DFS and Safety are secondary objectives (42). 
The latter,  ALINA, is  a more recent randomized 
phase III trial designed to directly compare alectinib 
administration versus gold-standard treatment in ALK+ 
patients, histologically confirmed as IB (T ≥4 cm) to IIIA 
stage and surgically resected at 4–12 weeks before the 
enrollment. Stage IIIA(N2) patients potentially candidates 
to radiotherapy are not included (being considered a 
confounding high-risk subgroup). The experimental arm 
requires continuous therapy with alectinib at classical 
schedule of 600 mg bid for 24 months, whilst in the 
control arm patients receive platinum-based chemotherapy 
for 4 cycles. Primary endpoint is DFS and, secondary 
objective OS. Furthermore, alectinib’s pharmacokinetic 
features and possible adverse events are monitored 
during administration. The study, started in 2018, will 
be terminated in 2023, with an estimated sample of 255 
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patients (43).
Alectinib, even more than crizotinib, is a well-tolerated 
therapy with a spectrum of adverse events typical of TKI 
and more manageable than chemotherapy, although rare 
serious adverse events may happen with new-generation 
TKI (1,44,45). Therefore, a long-course treatment in 
completely resected ALK+ patients is worthwhile if a real 
impact on long-term survival is obtained. As observed for 
EGFR+ lung cancer patients, initial exciting results, in 
terms of disease recurrence control, are impermanent and 
survival curves tend to converge and overlap after 4 years 
follow-up (39,40). Consequently, major results in adjuvant 
approaches could be attested only by mature and complete 
OS data, as the ALCHEMIST trial should provide (42). 
Multiple ALK inhibitors are available in the clinical arena 
and one puzzling issue, for peri-operative management 
of ALK+ NSCLC, is the selection of the correct TKI to 
be administered, in order to gain the best clinical benefit 
avoiding dangerous adverse events and disease’s molecular 
hijacking (46). 
Development of genotype-directed clinical trials in the 
adjuvant setting is encumbered by the need of large patients 
recruitment, the identification of a specific targetable 
alteration in early-stage tumors and the timeframe of 
long-term follow-up, making them often less attractive. 
Therefore, clinical trials exploring drugs’ efficacy in this 
setting need to be carefully planned; for instance, the 
ALCHEMIST trial has been designed in order to overcome 
these limitations (42). One major challenge is due to the 
identification of quite rare molecular alterations in early-
stage tumors, avoiding positive patients’ leak. Taking 
advantage of modern next-generation platforms, which give 
the opportunity of multi-gene analyses both at DNA and 
RNA level, we should consider the opportunity of screen 
the entire population of resected lung tumors in order to 
get a comprehensive molecular sub-stratification. With 
these data available at baseline, clinicians will be able to 
more easily and largely enroll patients within genotype-
restricted adjuvant trials. 
Biological challenges of adjuvant therapy 
As we learned from experience acquired targeting ALK 
oncogene in the advanced stage, TKIs are able to inhibit 
cell proliferation, hindering tumor growth in terms of 
dimension and number of metastatic sites, rather than 
eradicate the disease. Thus, residual neoplastic cells persist 
and eventually become resistant to targeted therapies 
(47,48). Drug-sensitive tumor cells can have growth 
flare at therapy discontinuation or respond again at 
re-treatment, meaning that these cells can be curbed, but 
non totally killed by TKI, even of more potent-generation. 
This growth-suppressant property of ALKi poses a major 
concern about ALK targeting as adjuvant treatment, 
whose aim is to eliminate microscopically residual disease. 
It is more beneficial to treat patients with undetectable 
tumor cells or at evidence of macroscopic relapse? 
Does TKI adjuvant treatment have the same long-term 
survival impact than administration at disease recurrence? 
Reasonably, only OS data of ongoing clinical trials will 
answer clear-cutting to these questions, ironing out any 
doubts about worthiness of adjuvant therapy in oncogene-
addicted patients (49). 
Neoplastic lesions are composed of heterogeneous cells 
population and, under pharmacological pressure imposed 
by TKI, clones with different biological behaviors emerge. 
Among them, a subpopulation of cells is able to enter in a 
reversible cell-cycle arrest phase becoming “dormant” or 
“quiescent”. In this state, cancer cells not longer affected 
by TKI exposure, tend to acquire other genetic mutations, 
to undergo epigenetic modifications and to hijack tumor 
microenvironment eluding immune-control (50-53). Thus, 
persister/tolerant cells represent a reservoir of resistance 
mechanisms to targeted therapies and, once these take over 
control, tumor lesions start to grow again (48). Unfortunately, 
little is known about underpinning molecular events 
driving this “persistent” phenotype and whether ALK-
targeting adjuvant therapies may cause accumulation of 
this cancer cells subset, altering biological history of the 
disease, is still to be defined. Relevant insights will be 
gained through clinical trials, ongoing or planned (i.e., 
NCT03088930 and PROMISE trials), in the neo-adjuvant 
setting, taking advantage of the opportunity to analyze 
residual tumor tissues after TKI exposure (8,30,54). A 
deep characterization of residual tumor cells and associated 
tumor microenvironment represents a unique chance to 
deeply study TKI-induced early molecular alterations 
driving future resistance to targeted therapies.
Recent advances in circulating tumor DNA (ctDNA) 
detection and analyses are changing clinical approach for 
cancer patients, even in the setting of early stage NSCLC; 
it’s possible to trace molecular evolution (i.e., identification 
of resistance mutations) influencing therapeutic strategies 
in the advance stage, follow clonal heterogeneity of 
cancer, help early cancer stage screening and also detect 
minimal residual disease (MRD) in resected patients 
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(55-62). Identification of MRD has been identified as a 
robust marker of impending disease recurrence both in 
hematological and solid tumors (63-65), therefore helping 
in risk stratification of early stage patients (Figure 1). With 
new available technologies and the application of next 
generation sequencing on surgical specimens is possible to 
design patient-specific MRD panel, covering specific tumor-
associated mutations rather than the entire genome (65). 
This implies multiple questions in the management of 
early stage ALK+ and other oncogene-addicted lung cancer 
patients: adjuvant therapy should start immediately to all 
patients after surgery or only at MRD positivity? Should it 
be monitored with blood-based targeted genomic changes 
and how often checked? Which is the right threshold (as 
absolute number or raising rate) defining patients that have 
to be treated? Are there specific MRD+ positive subgroups 
with higher risk of relapse (i.e., EML4-ALK fusion variant 
V3 and/or TP53 co-mutations) (66)?
The limited available experience in the adjuvant setting, 
mainly acquired on EGFR+ patients, is based on second-
generation inhibitors and little is now about last-generation, 
more potent TKI and their influence on tumor’s biology; 
data from ongoing trials will provide relevant insights 
(41,43). Adjuvant treatments are administered for a specific 
timeframe (i.e., 24 months) and resistance mechanisms 
may not suddenly emerge. Nevertheless, drug-tolerant cell 
clones can proliferate and potentially hijack tumor evolution 
generating resistant phenotypes. Future perspectives should 
take in consideration also alternative strategies in order to 
prevent these phenomena: safe combination of drugs (given 
together or as switching therapies) targeting different 
signalling pathways; intermitting administrations which may 
control tumor heterogeneity and development of resistant 
clones; reprogramming agents (e.g., epigenetic modifiers) 
able to interfere with tumor cells adaptation and tumor-
stroma interaction (67,68) (Figure 1).
The bet of adjuvant therapies with targeted agents 
in oncogene addicted NSCLC is to really improve 
chances of cure ensuring low risks for patients: minimize 
TKI-related adverse events and avoid molecular disruption 
Alternative strategies:
• Drugs combination
• Drugs switching
• lntermitting therapies
• Epigenetic reprogramming
• Tumor-stroma interference
IB-IIIA ALK + 
NSCLC 
Follow up 
MRD-
MRD+
MRD+ALECTINIB
Until 24 months LORLATINIB
ALECTINIB
DR- DR+
DR+ PD
DR+
Figure 1 Hypothetic adjuvant approaches to early-stage ALK+ NSCLC. This chart shows potential therapeutic approaches to early-
stage (IB–IIIA) ALK-rearranged NSCLC, not currently supported by clinical evidence. Contemplating risk stratification through MRD 
quantification, second and third-generation TKIs are taken into account as future key drugs, as well as other supposed strategies aimed to 
improve disease control rate and patients’ overall survival. ALK, anaplastic lymphoma kinase; NSCLC, non-small cell lung cancer; MRD, 
minimal residual disease; DR, disease recurrence; PD, progressive disease; TKI, tyrosine kinase inhibitor.
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of ALK-rearranged disease, preserving future therapeutic 
opportunities. 
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